Phase 4 N=156 Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
Vivax Malaria
Primary: Number of Patients Experiencing P. Vivax Recurrence — 48; 11; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=86 Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
Hip Arthroscopy
Primary: Change in Pain Score — 4.3; 4.4; 1.8; 1.7 score on a scale
Phase 4 N=61 Optimal Blood Pressure Treatment Thresholds Postpartum
Hypertensive Disorder of Pregnancy · Pre-Eclampsia · Hypertension
Primary: Percent of Participants Eligible, Enrolled and Retained (Feasibility) — 61 Participants
Phase 4 N=40 IV Ketorolac on Platelet Function Post-Cesarean Delivery
Analgesia, Obstetrical · Coagulation Defect; Postpartum · Nonsteroidals (NSAIDs)Toxicity
Primary: Platelet Aggregometry — 65.4; 59.1 Percentage of light transmission
Phase 4 N=5 To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.
Cellulite
Primary: Proportion of Subjects With ≥1-point Improvement on Investigator Global Aesthetic Improvement Scale (I-GAIS) at Day 90 (Buttocks) — 3; 2 Participants
Phase 4 N=1,995 Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana
Tuberculosis · HIV Infections
Primary: Number of Participants With Incident Tuberculosis — 20; 34 Participants
Phase 4 N=70 Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
Invasive Fungal Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 55; 9 Participants
Phase 4 N=115 Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery
Hypotension During Surgery · Blood Loss, Surgical
Primary: Surgeon's Analysis of Surgical Field Visualization — 1.3 score on a scale
Phase 4 N=26 Impact of Astaxanthin on Cognition in Recreationally Active Females
Mental Fatigue
Primary: Reaction Time — 402.7; 400; 426.4; 406.6 milliseconds
Phase 4 N=37 Cannabidiol for Bilateral Total Knee Arthroplasty
Pain, Postoperative · Opioid Use · Knee Osteoarthritis
Primary: Cumulative Opioid Usage in First 72 Hours Postoperatively — 209.0; 144.0; 203.2 Morphine Milligram Equivalents (MME)
Phase 4 N=615 Screening Contrast-Enhanced Mammography as an Alternative to MRI
Breast Cancer
Primary: Cancer Detection Rate (CDR) Per 1,000 Screenings — 8.3; 18.3 CDR per 1,000 screenings
Phase 4 N=658 Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
Migraine
Primary: Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) — -2.1; -0.5 Migraine Days per month — p=<0.0001
Phase 4 N=54 A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
Uncontrolled Gout · Chronic Gout
Primary: Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 68.0; 73.1 percentage of participants
Phase 4 N=162 Dexamethasone for Post Traumatic Headache
Post-Traumatic Headache
Primary: Frequency of Moderate or Severe Headache After Emergency Department (ED) Discharge — 31; 29; 42; 44 Participants — p=0.751
Phase 4 N=76 Neurobiological Underpinnings of Placebo Response in Depression
Depression
Primary: HAM-D 32 — 33.2; 16.50; 16.00; 16.7 Total score